<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Samsung Biologics, Amgen and Biocon invest in US pharma sites</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Samsung Biologics, Amgen and Biocon invest in US pharma sites</h1>
  <ul>
<li>Prior to that, it landed a $1.2 billion manufacturing contract with an Asia-based pharmaceutical company in October 2024.</li>
<li>The company said it has invested more than $40 billion in manufacturing and R&amp;D since the passage of the Tax Cuts and Jobs Act of 2017.</li>
<li>Amgen designated about $5 billion for U.S.</li>
<li>In April, Samsung Biologics inked a separate $514 million deal with an undisclosed U.S.</li>
<li>In 2020, Samsung Biologics opened a laboratory in San Francisco and continues to weigh U.S.</li>
<li>It is the second-biggest since the company’s founding in 2011, Korea JoongAng Daily reported.</li>
<li>pharma South Korea-based Samsung Biologics has struck a nearly $1.3 billion supplier deal with an undisclosed U.S.</li>
</ul>
<p><a href="https://finance.yahoo.com/m/e5f25881-fff5-3199-870d-760af03a56cc/samsung-biologics%2C-amgen-and.html">Source</a> · 2025-09-15T12:14:00+00:00</p>
</body>
</html>